Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS)

Elsallab, Magdi; Ellithi, Moataz; Lunning, Matthew A; D'Angelo, Christopher; MA, Jihyun; Perales, Miguel-Angel; Frigault, Matthew J; Maus, Marcela V

doi:10.1182/blood.2024024166

Second primary malignancies (SPMs) were reported in 536 out of 12,394 (4.3%) adverse event reports following CAR T cell therapies in the FDA Adverse Event Reporting System (FAERS). Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.

This content is only available as a PDF.

2024

Sign in via your Institution

Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS)

Article PDF first page preview

Supplemental data

Cited By

Email alerts

ASH Publications

American Society of Hematology

Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS)

Article PDF first page preview

Supplemental data

This feature is available to Subscribers Only

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only